| New Strong Sell Stocks for May 16th |
FBIO, AFCG and HRZN have been added to the Zacks Rank #5 (Strong Sell) List on May 16, 2025. |
zacks.com |
2025-05-16 10:51:05 |
Czytaj oryginał (ang.) |
| Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates |
Fortress Biotech (FBIO) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.03 per share a year ago. |
zacks.com |
2025-05-15 22:30:21 |
Czytaj oryginał (ang.) |
| Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2025. Lindsay A. |
globenewswire.com |
2025-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz. |
globenewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates |
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma |
globenewswire.com |
2025-05-13 20:15:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 |
Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET |
globenewswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference |
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following sessions at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference, taking place on Tuesday, May 13, 2025: |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer |
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer (“COO”). Mr. Alloush will continue to also serve as the Company's General Counsel. |
globenewswire.com |
2025-04-01 20:01:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates |
Fortress Biotech (FBIO) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.53 per share a year ago. |
zacks.com |
2025-03-31 22:50:49 |
Czytaj oryginał (ang.) |
| Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights |
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2024. Lindsay A. |
globenewswire.com |
2025-03-31 20:05:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates |
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma |
globenewswire.com |
2025-03-28 10:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript |
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - CFO Srinivas Sidgiddi - VP, R&D Louis Donati - Director, Market Access Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - ROTH Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-03-26 21:39:53 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights |
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz. |
globenewswire.com |
2025-03-26 18:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea |
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the launch of and the first prescriptions filled for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults. |
globenewswire.com |
2025-03-24 10:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 |
Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET |
globenewswire.com |
2025-03-19 18:01:00 |
Czytaj oryginał (ang.) |
| Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform |
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress. |
globenewswire.com |
2025-03-17 10:55:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Participate in the 37th Annual ROTH Conference |
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 37th Annual ROTH Conference, which is being held March 16-18, 2025 in Dana Point, California. |
globenewswire.com |
2025-03-12 10:30:00 |
Czytaj oryginał (ang.) |
| CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma |
NEW YORK , March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Industries, Inc. The firm is concerned about conflicts relating to Checkpoint's controlling shareholder, Fortress Biotech, Inc. (Nasdaq: FBIO), which has secured special benefits in the deal. For a free consultation, or to learn more, contact partner W. |
prnewswire.com |
2025-03-10 20:41:00 |
Czytaj oryginał (ang.) |
| Sun Pharma to Acquire Checkpoint Therapeutics |
Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence toaccelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4.10 per share of common stock,representing aggregate upfront consideration of up to $355 million Stockholders will also receive a contingent value right forup to $0.70 per share on achievement of a milestone Acquisition is subject to approval by Checkpoint's stockholdersand other customary closing conditions MUMBAI, India and WALTHAM, Mass., March 9, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. |
prnewswire.com |
2025-03-10 00:06:00 |
Czytaj oryginał (ang.) |
| Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement |
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1). |
globenewswire.com |
2025-03-05 18:15:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) |
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma |
globenewswire.com |
2024-12-13 20:15:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights |
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2024. Lindsay A. |
globenewswire.com |
2024-11-14 18:10:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates |
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates. |
globenewswire.com |
2024-11-12 18:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights |
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea |
Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. |
globenewswire.com |
2024-11-04 09:00:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference |
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects |
globenewswire.com |
2024-10-25 12:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference |
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will attend one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, scheduled to take place on Wednesday, October 9, 2024 in New York City. |
globenewswire.com |
2024-10-03 12:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech to Participate in October 2024 Investor Conferences |
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following upcoming October 2024 investor conferences: |
globenewswire.com |
2024-09-26 12:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements |
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that on September 19, 2024 it entered into securities purchase agreements with healthcare focused institutional investors for the issuance and sale of 3,939,394 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering at a purchase price of $1.65 per share. In a concurrent private placement, the Company also agreed to issue to the same investors warrants to purchase up to 3,939,394 shares of common stock. The private placement warrants have an exercise price of $1.84 per share, will be exercisable commencing six months from the date of issuance, and will expire five and one-half years following the date of issuance. |
globenewswire.com |
2024-09-20 12:30:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 |
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 |
globenewswire.com |
2024-09-16 11:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference |
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will attend one-on-one meetings at the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference, scheduled to take place on Thursday, September 12, 2024 in New York City. |
globenewswire.com |
2024-09-09 12:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference. |
globenewswire.com |
2024-09-04 12:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference. |
globenewswire.com |
2024-09-04 12:15:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference |
WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference. |
globenewswire.com |
2024-09-04 12:00:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock |
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. |
zacks.com |
2024-09-02 13:51:05 |
Czytaj oryginał (ang.) |
| Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates |
Fortress Biotech (FBIO) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $3.60 per share a year ago. |
zacks.com |
2024-08-13 22:15:22 |
Czytaj oryginał (ang.) |
| Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights |
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults |
globenewswire.com |
2024-08-13 20:05:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights |
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz. |
globenewswire.com |
2024-08-12 20:01:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates |
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates. |
globenewswire.com |
2024-08-12 12:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024 |
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET |
globenewswire.com |
2024-08-06 20:01:00 |
Czytaj oryginał (ang.) |